Pathway Medical Technologies' Jetstream G3
This article was originally published in The Gray Sheet
Executive Summary
Firm gains 510(k) clearance for its Jetstream G3 peripheral atherectomy catheter for the treatment of peripheral vascular disease, Pathway announces Jan. 13. G3 features a new distal cutter and enhanced aspiration efficiency, allowing the device to cut and remove disease better than previous versions, the company notes. The new device will be "particularly desirable for long, diffusely diseased segments, including calcifications, chronic total occlusions and traditional 'no stent' zones," according to cardiologist Tom Shimshak, M.D., who is quoted in the company's release. Pathway Medical's G2 catheter launched in February 2009 (1"The Gray Sheet" Feb. 9, 2009)
You may also be interested in...
Pathway Medical Technologies’ Jetstream G2
Endovascular device maker launches second-generation Jetstream G2 peripheral atherectomy catheter for removing plaque, calcium buildup, thrombus and fibrotic lesions in lower limb arteries after receiving 510(k) clearance Feb. 2. Peripheral artery disease affects around 12 million Americans and is associated with high blood pressure, diabetes, heart disease, stroke and aging, the firm says. Jetstream G2's design enhancements over the first-generation Jetstream, which received FDA clearance in September 2008, include an aspiration port that is separate from the cutting mechanism to provide greater aspiration efficiency and a masticating system located within the port to help break aspirated material into smaller pieces before removal, the firm explains
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.